Ep134: Emile Nuwaysir on In Vivo Gene Editing Therapies
Listen now
Description
Emile Nuwaysir, CEO of Boston-based Ensoma, on developing off-the-shelf in vivo gene editing therapies.
More Episodes
David Younger and Randolph Lopez, co-founders of A-Alpha Bio, on using synthetic biology and AI to discover new biologic drugs.
Published 05/20/24
Published 05/20/24
Vineeta Agarwala, general partner at A16Z's Bio & Health fund, on investing in AI for drug discovery.
Published 05/01/24
Links
Genres
Artwork or description wrong?
Request an update »
Updates may take a few minutes.
Do you host a podcast?
Track your ranks and reviews from Spotify, Apple Podcasts and more.
See hourly chart positions and more than 30 days of history.
Get Chartable Analytics »
See hourly chart positions and more than 30 days of history.
